InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.50.

A number of research analysts have commented on IFRX shares. Wall Street Zen downgraded InflaRx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Leerink Partnrs downgraded shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Leerink Partners reissued a “market perform” rating and set a $2.00 target price (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Finally, Guggenheim raised their price target on shares of InflaRx from $10.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, November 10th.

Hedge Funds Weigh In On InflaRx

A number of hedge funds and other institutional investors have recently bought and sold shares of IFRX. Concurrent Investment Advisors LLC acquired a new stake in shares of InflaRx during the 2nd quarter worth approximately $65,000. Squarepoint Ops LLC grew its stake in InflaRx by 29.1% during the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after buying an additional 42,489 shares during the last quarter. Boothbay Fund Management LLC increased its position in InflaRx by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after buying an additional 17,056 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in InflaRx by 158.3% in the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after buying an additional 91,927 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Stock Performance

IFRX opened at $1.04 on Friday. The company has a market capitalization of $69.82 million, a P/E ratio of -1.53 and a beta of 1.44. The company has a 50-day moving average of $1.16 and a 200-day moving average of $1.14. InflaRx has a 1-year low of $0.71 and a 1-year high of $2.77.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. As a group, sell-side analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.